
|Articles|February 26, 2007
Helixate FS, Mix2Vial now packaged together
Advertisement
CSL Behring has begun packaging Helixate FS, its advanced recombinant FVIII (rFVIII) factor product for the treatment of hemophilia A, with Mix2Vial, its needle-free transfer device. The new packaging was developed in response to comprehensive market research of customers and to meet the latest OSHA requirements. For more information, visit
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 Infection During First Trimester Increases Risk of Neonatal Risks
2
Maximizing Efficiency and Expansion of Vaccine Offerings in Pharmacy
3
Older Adults Lack Understanding of OTC Drugs Despite Common Use
4
Half of Patients Have Used Online Pharmacies But Under 10% Identified Safe Sites
5












































































































































